Welcome back! Whether you are an old friend or a recent acquaintance, we look forward to catching up with you frequently over our Pharm Forward blogs.  We are excited to put our pen back on paper for these ongoing exchanges with you on the rapidly evolving yet high impact world of global pharma and biotech.  While we spend our days working with clients to steer growth, transform value chains and shape the pharma and biotech world for the next decade, we enjoy moon lighting on these open interactions with you on our PharmForward Blog.

As before, we promise to be pragmatic yet reflective and forward looking.   The only certain aspect of the world around us today is, uncertainty.   That means it is more important than ever today that you are well informed about developments across the world and across business segments. Post-COVID, focus on regional value chains has become a priority across global regions.   Pharma and biotech capacity are now undeniably acknowledged as the nucleus of health security and health system resilience.  Hence, this quest for regional value chains is true across both high-income countries as well as low and middle-income countries.  This focus on a new world order in pharma has significant ramifications for industry and calls for deft and strategic pursuit of growth pathways. At the other end, for the Champions of regional ecosystems, solutions aren’t apparent or easy.  Sustained success requires strategic and well-conceived initiatives that foster a foundation for the future.

While the global manufacturing capacity is reshaped, innovation dynamics are also rapidly evolving.  New global hubs of R&D are gaining prominence as source of the biopharma pipeline of the future.  AI and technology investments emphasize the promise of more discovering the next new drug at a fraction of the time and cost of historical benchmarks.  Does this imply an opportunity for new entrants to win the land of the goliaths? For both the Davids and the Goliaths, the opportunity continues to be expansive – unmet clinical needs are many, across the higher value world of biologicals and peptides, and continuing use of small molecules that win on cost as well as ease of use.

Join us for regular updates and engaging conversations, across the spectrum of commercial opportunity, policy environment, transactions,
ESG and regulatory developments.

Author: